Sorrento Therapeutics (OTC: SRNE) reached the definitive end of its Chapter 11 journey on July 24, 2026, with court approval for its liquidation plan. This pivotal decision confirms a near-total loss for existing shareholders, as the winding-down process prioritizes creditors and systematically blocks attempts at equity recovery. The company’s stock, trading at a negligible $0.00, reflects the grim reality that any hope for shareholder value has been extinguished.
Key Takeaways
- Sorrento Therapeutics’ Chapter 11 liquidation plan, approved on July 24, 2026, formalizes the complete erosion of shareholder value, with the stock currently trading at $0.00.
- Recent court rulings, including the blocking of a shareholder RICO suit in June 2026,…